Korro Bio, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
KRRO$15.73+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating Activities: | ||
| Net loss | $(19,625) | $(23,387) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash lease expense | 242 | 158 |
| Stock-based compensation expense | 2,731 | 1,761 |
| Depreciation expense | 380 | 1,225 |
| Net amortization of premiums and discounts on marketable securities | 2 | (340) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 969 | (228) |
| Prepaid expenses and other current assets | 54 | (617) |
| Accounts payable | (153) | 99 |
| Accrued expenses and other current liabilities | (205) | (2,511) |
| Deferred revenue | — | (626) |
| Operating lease liabilities | (601) | 420 |
| Other non-current assets | 132 | (406) |
| Net cash used in operating activities | (16,074) | (24,452) |
| Investing Activities: | ||
| Purchases of marketable securities | (45,219) | — |
| Proceeds from maturities of marketable securities | 13,000 | 32,900 |
| Purchases of property and equipment | (21) | (119) |
| Net cash (used in) provided by investing activities | (32,240) | 32,781 |
| Financing Activities: | ||
| Proceeds from the issuance of common stock in connection with the at-the-market program, net of offering costs | 5,041 | — |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with the private placement, net of offering costs | 83,154 | — |
| Proceeds from exercises of stock options | 17 | 172 |
| Net cash provided by financing activities | 88,212 | 172 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (25) | — |
| Net increase in cash, cash equivalents and restricted cash | 39,873 | 8,501 |
| Cash, cash equivalents and restricted cash, beginning of period | 25,230 | 59,049 |
| Cash, cash equivalents and restricted cash, end of period | $65,103 | $67,550 |
| Non-cash investing and financing activities: | ||
| Purchases of property and equipment in accounts payable and accrued expenses | $— | $120 |
| Offering costs in accounts payable and accrued expenses | $2,917 | $— |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $48 | $— |
| Cash paid for operating lease liabilities | $1,782 | $501 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.